trending Market Intelligence /marketintelligence/en/news-insights/trending/OFcDf7kWGRKQLGZdQGSXUw2 content esgSubNav
In This List

Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Trillium Therapeutics Inc. is cutting 17 jobs as part of a restructuring to focus its resources on the development of cancer treatments.

According to the company's Oct. 22 press release, the 40% reduction in staff is effective immediately, with 26 active employees remaining. The Mississauga, Ontario-based biotechnology company is looking for a partner for further development of its STING agonist program — a treatment that enhances the immune system to fight cancer tumors.

The company also plans to cut expenses through discontinuing its discovery research activities and through operational efficiencies.